You just read:

ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development

News provided by

ProMIS Neurosciences Inc.

Aug 21, 2018, 07:30 ET